Rarecells, Inc.

ISET® test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells

Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine's (Melbourne, Australia) researchers obtained striking results in a group of …

OTE0002
28.10.2020 09:01